Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Express Scripts
Mallinckrodt
McKesson
AstraZeneca

Last Updated: January 26, 2023

CLINICAL TRIALS PROFILE FOR GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Glimepiride; Pioglitazone Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00225264 ↗ Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease. Completed Takeda Phase 3 2003-10-01 The primary purpose of this study is to compare the effects of pioglitazone, once daily (QD), versus glimepiride on the amount of thickening of the carotid artery.
NCT00225277 ↗ Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus Completed Takeda Phase 3 2003-07-01 The purpose of this study was to determine the efficacy of pioglitazone, once daily (QD), compared to glimepiride on atherosclerotic disease measured by intravascular ultrasound.
NCT00576784 ↗ Metabolic Effects of Pioglitazone in Type II Diabetic Patients Previously Treated With Insulin Completed IKFE Institute for Clinical Research and Development Phase 4 2005-04-01 The goal of the study is to demonstrate whether a switch from insulin therapy to an oral therapy with pioglitazone/glimepiride will lead to a deterioration of glycemic control (increase in HbA1c by more than 0.5 %) within a 6 month observation period.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Glimepiride; Pioglitazone Hydrochloride

Condition Name

Condition Name for Glimepiride; Pioglitazone Hydrochloride
Intervention Trials
Type 2 Diabetes Mellitus 6
Diabetes Mellitus 4
Diabetes Mellitus, Type 2 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Glimepiride; Pioglitazone Hydrochloride
Intervention Trials
Diabetes Mellitus, Type 2 15
Diabetes Mellitus 15
Insulin Resistance 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Glimepiride; Pioglitazone Hydrochloride

Trials by Country

Trials by Country for Glimepiride; Pioglitazone Hydrochloride
Location Trials
United States 127
Germany 32
Canada 12
Italy 10
United Kingdom 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Glimepiride; Pioglitazone Hydrochloride
Location Trials
Florida 4
Oklahoma 4
California 4
Louisiana 4
Minnesota 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Glimepiride; Pioglitazone Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Glimepiride; Pioglitazone Hydrochloride
Clinical Trial Phase Trials
Phase 4 9
Phase 3 7
N/A 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Glimepiride; Pioglitazone Hydrochloride
Clinical Trial Phase Trials
Completed 14
Unknown status 4
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Glimepiride; Pioglitazone Hydrochloride

Sponsor Name

Sponsor Name for Glimepiride; Pioglitazone Hydrochloride
Sponsor Trials
Takeda 6
IKFE Institute for Clinical Research and Development 2
Forest Laboratories 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Glimepiride; Pioglitazone Hydrochloride
Sponsor Trials
Other 15
Industry 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Dow
AstraZeneca
Boehringer Ingelheim
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.